Jove
Visualize
Contact Us

Related Concept Videos

Antihypertensive Drugs: Action of Diuretics01:16

Antihypertensive Drugs: Action of Diuretics

Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various tubules...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Urinary Tract Calculi III: Medical Management01:30

Urinary Tract Calculi III: Medical Management

The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association between estimated time with low glomerular filtration rate and access to transplant among youth with advanced chronic kidney disease.

Pediatric nephrology (Berlin, Germany)·2026
Same author

Bilateral Glomerulocystic Kidney Disease With Extensive Embryonal Hyperplasia in a Setting of <i>HNF1B</i> Mutation.

Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society·2026
Same author

Dosing trajectories of antihypertensive agents among preterm neonates: A retrospective, cross-sectional analysis.

PloS one·2025
Same author

Sequence of antihypertensive medications used in preterm infants with hypertension: A cross-sectional study.

PloS one·2025
Same author

Sugar, salt, immunity and the cause of primary hypertension.

Clinical kidney journal·2023
Same author

Adverse childhood experiences are associated with vascular changes in adolescents that are risk factors for future cardiovascular disease.

Pediatric nephrology (Berlin, Germany)·2023
Same journal

Current Options for Kidney Protection: Are Renin-Angiotensin System Inhibitors Still Relevant?

Seminars in nephrology·2026
Same journal

Proposed Role for Quantitative Podocyturia as a Clinical Marker of Systemic Endothelial Injury: Implications for Cardiovascular Disease and Longevity.

Seminars in nephrology·2026
Same journal

Kidney Protection Options in 2025: Are Renin-Angiotensin System Inhibitors Still Needed?

Seminars in nephrology·2026
Same journal

From Nephron Number to Global Health.

Seminars in nephrology·2026
Same journal

Chronic Kidney Disease Progression Mechanisms: Why They Matter in an Era of Novel Kidney Protective Therapies.

Seminars in nephrology·2026
Same journal

Of Diuretics, Transporters, and Mechanisms of Hypertension.

Seminars in nephrology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 28, 2026

Quantitative SERS Detection of Uric Acid via Formation of Precise Plasmonic Nanojunctions within Aggregates of Gold Nanoparticles and Cucurbit[n]uril
10:02

Quantitative SERS Detection of Uric Acid via Formation of Precise Plasmonic Nanojunctions within Aggregates of Gold Nanoparticles and Cucurbit[n]uril

Published on: October 3, 2020

Uric acid and hypertension.

Daniel I Feig1

  • 1Division of Nephrology, Department of Pediatrics, University of Alabama, Birmingham School of Medicine, Birmingham, AL 35233, USA. dfeig@peds.uab.edu

Seminars in Nephrology
|October 18, 2011
PubMed
Summary
This summary is machine-generated.

Serum uric acid may contribute to hypertension through a two-step process involving the renin-angiotensin system and nitric oxide. While animal models and initial trials show promise, reducing uric acid is not yet a primary hypertension treatment.

Related Experiment Videos

Last Updated: May 28, 2026

Quantitative SERS Detection of Uric Acid via Formation of Precise Plasmonic Nanojunctions within Aggregates of Gold Nanoparticles and Cucurbit[n]uril
10:02

Quantitative SERS Detection of Uric Acid via Formation of Precise Plasmonic Nanojunctions within Aggregates of Gold Nanoparticles and Cucurbit[n]uril

Published on: October 3, 2020

Area of Science:

  • Cardiovascular Medicine
  • Nephrology
  • Metabolic Diseases

Background:

  • The association between serum uric acid and hypertension has been observed for decades.
  • Recent research has focused on understanding the underlying mechanisms linking uric acid to hypertension.
  • Epidemiologic studies suggest a correlation, prompting further investigation into its pathogenic role.

Purpose of the Study:

  • To elucidate the pathogenic mechanisms by which serum uric acid contributes to hypertension.
  • To investigate the role of uric acid in activating the renin-angiotensin system and suppressing nitric oxide.
  • To evaluate the potential of targeting uric acid for hypertension management.

Main Methods:

  • Review of animal models demonstrating a two-step pathogenesis of uric acid-induced hypertension.
  • Analysis of initial clinical trials in young patients assessing the impact of uric acid on hypertension.
  • Examination of uric acid's effects on systemic vascular resistance and renal vasculopathy.

Main Results:

  • Animal models suggest uric acid initially increases vascular resistance by activating the renin-angiotensin system and reducing nitric oxide.
  • A subsequent uric acid-mediated vasculopathy, particularly in renal afferent arterioles, leads to sodium-sensitive hypertension.
  • Early clinical trials support these mechanisms in young individuals but do not confirm uric acid reduction as a first-line therapy.

Conclusions:

  • Serum uric acid plays a complex role in hypertension development through distinct pathogenic steps.
  • Pharmacologic reduction of serum uric acid is not currently recommended as a primary treatment for hypertension.
  • Further research is needed to fully understand and potentially leverage the uric acid-hypertension link in clinical practice.